# WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, June 04, 2004

| Hide? | Set Name | Query | Hit Count |
|---|---|---|---|
| | *DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ* | | |
| ☐ | L14 | (igf1 or igf-1) same crystal$8 | 14 |
| ☐ | L13 | L11 and orthrohmbic | 0 |
| ☐ | L12 | L11 and c2221 | 1 |
| ☐ | L11 | L10 and diffraction | 100 |
| ☐ | L10 | L9 and (three adj1 dimensional structure or x-ray or 3-d structure) | 638 |
| ☐ | L9 | (IGF-1 or IGF1) and crystal$6 | 1369 |
| ☐ | L8 | (IGF-1 or IGF1) and $crystal6 | 0 |
| ☐ | L7 | IGF adj1 1 and $crystal6 | 0 |
| ☐ | L6 | L5 and atomic coordinate | 5 |
| ☐ | L5 | somatomedin and (three adj2 dimensional structure or 3-d structure or x-ray) | 399 |
| ☐ | L4 | somatomedin and (three adj3 structure or x-ray) | 414 |
| ☐ | L3 | somatomedin same crystal | 1 |
| ☐ | L2 | L1 and crystal | 325 |
| ☐ | L1 | somatomedin | 1529 |

END OF SEARCH HISTORY

# Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

**Search Results** - Record(s) 1 through 14 of 14 returned.

☐ 1. Document ID: US 20040105888 A1

**Using default format because multiple data bases are involved.**

L14: Entry 1 of 14 File: PGPB Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040105888
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040105888 A1

TITLE: Buoyant polymer particles for delivery of therapeutic agents to the central nervous system

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Pratt, Daniel | Amesbury | MA | US | |
| MacAusland, Samuel S. | Wellesley | MA | US | |
| Baker, Keith | Danvers | MA | US | |

US-CL-CURRENT: 424/486

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 2. Document ID: US 20030148968 A1

L14: Entry 2 of 14 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148968
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148968 A1

TITLE: Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Hammond, H. Kirk | La Jolla | CA | US | |
| Dillmann, Wolfgang | Solana Beach | CA | US | |

Giordano, Frank J. Madison CT US

US-CL-CURRENT: 514/44; 604/500

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

---

☐ 3. Document ID: US 20030124197 A1

L14: Entry 3 of 14 File: PGPB Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030124197
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030124197 A1

TITLE: Compositions and methods for improving integrity of compromised body passageways and cavities

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Signore, Pierre E. | Vancouver | | CA | |
| Machan, Lindsay S. | Vancouver | | CA | |

US-CL-CURRENT: 424/499; 424/501, 514/283, 514/449, 514/54, 514/55

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

---

☐ 4. Document ID: US 20030092631 A1

L14: Entry 4 of 14 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092631
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092631 A1

TITLE: IGF antagonist peptides

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Deshayes, Kurt D. | San Francisco | CA | US | |
| Lowman, Henry B. | El Granada | CA | US | |
| Schaffer, Michelle L. | Cambridge | CA | GB | |
| Sidhu, Sachdev S. | San Francisco | | US | |

US-CL-CURRENT: 514/14; 530/326

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 20030054973 A1

L14: Entry 5 of 14 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054973
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054973 A1

TITLE: Methods and compositions for the repair and/or regeneration of damaged myocardium

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Anversa, Piero | New York | NY | US | |

US-CL-CURRENT: 514/1; 435/372

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 6. Document ID: US 20030050262 A1

L14: Entry 6 of 14 File: PGPB Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030050262
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030050262 A1

TITLE: Inhibition of neurodegeneration

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Wands, Jack R. | Waban | MA | US | |
| Monte, Suzanne M. de la | East Greenwich | RI | US | |

US-CL-CURRENT: 514/44; 435/368

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 7. Document ID: US 20030027202 A1

L14: Entry 7 of 14 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027202
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027202 A1

TITLE: Methods of screening compounds for bioactivity in organized tissue

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Vandenburgh, Herman H. | Providence | RI | US | |
| Valentini, Robert F. | Cranston | RI | US | |

US-CL-CURRENT: 435/6; 435/4, 435/7.21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

---

☐ 8. Document ID: US 20020165155 A1

L14: Entry 8 of 14 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165155
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165155 A1

TITLE: Crystallization of IGF-1

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Schaffer, Michelle | Cambridge | CA | GB | |
| Ultsch, Mark | Mill Valley | CT | US | |
| Vajdos, Felix | Ledyard | | US | |

US-CL-CURRENT: 514/12; 530/350, 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

---

☐ 9. Document ID: US 20020106627 A1

L14: Entry 9 of 14 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106627
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020106627 A1

TITLE: METHODS OF SCREENING COMPOUNDS FOR BIOACTIVITY IN ORGANIZED TISSUE

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| VANDENBURGH, HERMAN H. | PROVIDENCE | RI | US | |

VALENTINI, ROBERT F. CRANSTON RI US

US-CL-CURRENT: 435/4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 10. Document ID: US 20020022055 A1

L14: Entry 10 of 14 File: PGPB Feb 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020022055
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020022055 A1

TITLE: Composition and methods for immproving integrity of compromised body passageways and cavities

PUBLICATION-DATE: February 21, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Signore, Pierre E | Vancouver British Columbia | | CA | |

US-CL-CURRENT: 424/486

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 11. Document ID: US 6124259 A

L14: Entry 11 of 14 File: USPT Sep 26, 2000

US-PAT-NO: 6124259
DOCUMENT-IDENTIFIER: US 6124259 A

TITLE: Method for treating ophthalmic disorders with IGFBP

DATE-ISSUED: September 26, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Delmage; Michael J. | Scotts Valley | CA | | |
| Sommer; Andreas | Pleasanton | CA | | |

US-CL-CURRENT: 514/12; 435/69.1, 530/324, 530/350

ABSTRACT:

This is a method for treating ophthalmic disorders associated with an excess of IGF-I or IGF-II. The method comprises administering individuals with an IGF excess insulin-like growth factor binding protein (IGFBP). The preferred form is IGFBP-3.

14 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. D

☐ 12. Document ID: WO 2064627 A2

L14: Entry 12 of 14 File: EPAB Aug 22, 2002

PUB-NO: WO002064627A2
DOCUMENT-IDENTIFIER: WO 2064627 A2
TITLE: CRYSTALLIZATION OF IGF-1

PUBN-DATE: August 22, 2002

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| SCHAFFER, MICHELLE | |
| ULTSCH, MARK | |
| VAJDOS, FELIX | |

INT-CL (IPC): C07 K 14/65; C30 B 29/58
EUR-CL (EPC): C07K014/65

ABSTRACT:

Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method for identifying IGF-1 indirect agonists is provided using a detergent as a standard for the level of inhibition of binding of IGFBP-1 or IGFBP-3 to IGF-1 and/or using the coordinates of the binding pockets of IGF-1 to which a candidate indirect agonist binds for structure-based drug design.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. D

☐ 13. Document ID: WO 9928347 A1

L14: Entry 13 of 14 File: EPAB Jun 10, 1999

PUB-NO: WO009928347A1
DOCUMENT-IDENTIFIER: WO 9928347 A1
TITLE: METHOD OF DESIGNING AGONISTS AND ANTAGONISTS TO IGF RECEPTOR

PUBN-DATE: June 10, 1999

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|

| | |
|---|---|
| BENTLEY, JOHN DAVID | AU |
| COSGROVE, LEAH JANE | AU |
| FRENKEL, MAURICE JOHN | AU |
| GARRETT, THOMAS PETER JOHN | AU |
| LAWRENCE, LYNNE JEAN | AU |
| LOU, MEIZHEN | AU |
| LOVRECZ, GEORGE OSCAR | AU |
| MCKERN, NEIL MORETON | AU |
| TULLOCH, PETER ARCHIBALD | AU |
| WARD, COLIN WESLEY | AU |

INT-CL (IPC): C07 K 14/705; C07 K 14/71; G06 F 17/50; G06 F 19/00; G06 F 159/00
EUR-CL (EPC): C07K014/65

ABSTRACT:

CHG DATE=19990803 STATUS=O>The present invention relates to a method of designing compounds able to bind to a molecule of the insulin receptor family and to modulate the activity mediated by the receptor based on the 3-D structure coordinates of a IGF-1 receptor crystal of Figure 1.



☐ 14. Document ID: AU 2002255508 A1, WO 200264627 A2, US 20020165155 A1, EP 1358209 A2

L14: Entry 14 of 14 File: DWPI Aug 28, 2002

DERWENT-ACC-NO: 2002-723170
DERWENT-WEEK: 200427


TITLE: Crystal formed by insulin-like growth factor-1, IGF-1, useful for treating agonist disorders, diffracts x-ray radiation to produce a diffraction pattern representing the three-dimensional structure of IGF-1

INVENTOR: SCHAFFER, M; ULTSCH, M ; VAJDOS, F

PRIORITY-DATA: 2001US-287072P (April 27, 2001), 2001US-267977P (February 9, 2001), 2002US-0066009 (February 1, 2002)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| AU 2002255508 A1 | August 28, 2002 | | 000 | C07K014/65 |
| WO 200264627 A2 | August 22, 2002 | E | 067 | C07K014/65 |
| US 20020165155 A1 | November 7, 2002 | | 000 | A61K038/18 |
| EP 1358209 A2 | November 5, 2003 | E | 000 | C07K014/65 |

INT-CL (IPC): A61 K 38/18; C07 K 14/475; C07 K 14/65; C30 B 29/58; G01 N 33/48; G01

N 33/50; G06 F 19/00

ABSTRACTED-PUB-NO: WO 200264627A
BASIC-ABSTRACT:

NOVELTY - A crystal (I) formed by insulin-like growth factor-1 (IGF-1) that diffracts x-ray radiation to produce a diffraction pattern representing the three-dimensional structure of IGF-1, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a composition (II) comprising (I), and a carrier;

(2) crystallizing (M1) IGF-1, involves mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixed volume, and crystallizing the mixed volume;

(3) crystalline IGF-1 (III) produced by (M1);

(4) identifying (M2) indirect agonists of IGF-1, involves:

(a) comparing the ability of N,N-bis(3-D-gluconamidopropyl)- deoxycholamine to inhibit binding of IGF binding protein 1 (IGFBP-1) or IGFBP-3 to IGF-1 with the ability of a candidate indirect agonist of IGF-1 to inhibit binding, and determining whether the candidate agonist inhibits such binding as well as N,N-bis (3-D-gluconamidopropyl)-deoxychol- amine; or

(b) co-crystallizing a candidate direct agonist IGF-1 with IGF-1 to form a co-crystalline structure and determining if the candidate agonist binds to one or both of two patches on IGF-1, where one patch has the amino acid residues Glu3, Thr4, Leu5, Asp12, Ala13, Phe16, Val17, Cys47, Ser51, Cys52, Asp53, Leu54 and Leu57, and the second patch has the amino acid residues Val11, Gln15, Phe23, Phe25, Asn26, Val44, Phe49 and Arg55, and binding occurs if there is a contact between each listed amino acid residue of a given patch and the candidate agonist that is less than or equal to 6 Angstrom in the co-crystalline structure;

(5) a co-crystalline complex (IV) of IGF-1 and N,N-bis(3-D-gluconamidoprop- yl)-deoxycholamine;

(6) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data that, when read by an appropriate machine, displays a three-dimensional representation of a crystal of a molecule comprising IGF-1;

(7) an IGF-1 crystal (V) with the structural coordinates of fully defined in the specification;

(8) identifying (M3) IGF-1 agonists or antagonists, involves crystallizing IGF-1 to form IGF-1 crystals containing a group of amino acid residues defining an IGF-1 receptor-binding region, irradiating the IGF-1 crystals to obtain a diffraction pattern of the IGF-1 crystals, determining a three-dimensional structure of IGF-1 from the diffraction pattern, and identifying an IGF-1 agonist or antagonist having a three-dimensional structure that functionally duplicates essential IGF receptor-binding, solvent-accessible residues presenting the three-dimensional structure of the IGF-1 receptor-binding region, and has altered signal transduction capacity to IGF-1-responsive cells, as compared to IGF-1;

(9) identifying (M4) a peptidomimetic that binds IGF-1 and blocks binding of an IGFBP or a receptor that binds to IGF-1, involves searching a molecular structure database with the structural parameters or structural coordinates fully defined in

the specification, and selecting a molecule from the database that mimics the structural parameters or coordinates;

(10) determining (M5) a portion of a three-dimensional structure of a molecular complex comprising IGF-1, involves determining the structural coordinates of a crystal of IGF-1, calculating phases from the structural coordinates, calculating an electron density map from the obtained phases, and determining the structure of a portion of the complex based on the electron density map;

(11) evaluating (M6) the ability of a chemical entity to associate with IGF-1 or its complex, by employing computational or experimental unit to perform a fitting operation between the chemical entity and the IGF-1 or its complex, to obtain data related to the association, and analyzing the obtained data to determine the characteristics of the association between the chemical entity and the IGF-1 or its complex;

(12) a chemical entity (VI) identified by the above method, that interferes with in vivo or in vitro association between IGF-1 and its receptor or between IGF-1 and one of its binding proteins, or associates with a binding site on IGF-1;

(13) determining (M7) a three-dimensional structure of IGF-1, involves crystallizing the IGF-1, irradiating the crystalline IGF-1 to obtain a diffraction pattern characteristic of the crystalline IGF-1, and transforming the diffraction pattern into the three-dimensional structure of IGF-1; and

(14) a heavy-atom derivative (VII) of a crystallized form of IGF-1.

ACTIVITY - Antidiabetic; Anorectic; Cardiant; Anti-HIV; Immunostimulant.

MECHANISM OF ACTION - Agonist of IGF-1.

No biological data given.

USE - (I) including an IGF-1 receptor-binding region, is useful for identifying compounds having structures that interact with the receptor-binding region of the three-dimensional structure of IGF-1 and function as an IGF-1 agonist or antagonist. (II) is useful for treating a mammal, especially human suffering from an agonist disorder such as diabetes, obesity, heart dysfunction, acquired immunodeficiency syndrome (AIDS)-related wasting, kidney disorder, neurological disorder, whole body growth disorder or immunological disorder. (III) is useful for computationally or experimentally evaluating a chemical entity to obtain information about its association with a binding site of IGF-1. (M4) is useful for designing a compound that mimics the 3-dimensional surface structure of IGF-1 (claimed). (I) is useful as standard or control in a diagnosing setting, for e.g. as a molecular weight marker or ELISA, radioassay, radioreceptor assay control; and studying binding properties of IGF-1, IGFBPs and IGF-1 receptors. (III) is useful for designing chemical entities that bind to or associate with IGF-1, and for altering physical properties of the chemical entities in different ways. (IV) and indirect agonist identified by (M2) are useful for treating the above mentioned agonist disorders, including immuno-deficiencies, Turner's syndrome, insulin resistance and necrosis. (III) is useful for solving the crystal structures of mutants, co-complexes, or crystalline form of any other molecule homologous to or capable of associating with a portion of IGF-1.

DESCRIPTION OF DRAWING(S) - The figure shows a ribbon diagram of IGF-1 showing the backbone fold.

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

| Terms | Documents |
|---|---|
| (igf1 or igf-1) same crystal$8 | 14 |

**Display Format:** - Change Format

Previous Page Next Page Go to Doc#